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Dear Editor,
I read the recent article by Bacchi et al. in a recent issue of
your esteemed journal with great interest (1). The article is
highly thought provoking. Over the past few years, new data
have emerged that reveal the emerging role of epidermal
growth factor (EGF) and its receptor (EGFR) in the personaliza-
tion of non-small cell lung cancer (NSCLC) treatment.
Currently, EGFR tyrosine kinase inhibitors (TKIs), such as
erlotinib and gefitinib, have been demonstrated to be
effective in prolonging progression-free survival (PFS) and
overall survival (OS) in patients with advanced NSCLC and
EGFR mutations in exon 19 and 21 (2). In 2009, Rosell et al.
reported EGFRmutations in 16.6% of lung cancer patients in
a Spanish study (3). In that study, the median PFS and
median OS were 14 months and 27 months, respectively (3).
A Japanese study conducted by Tanaka et al. confirmed that
EGFR mutations are more frequent in the adenocarcinoma
histological type and in light smokers (4). In Tanaka’s study,
the overall frequency of EGFR mutations was 31% (4).
Kosaka et al. conducted a study in Japan in 397 patients with
lung adenocarcinoma who underwent potentially curative
pulmonary resection (5). They found that 196 patients (49%)
had EGFR mutations. Of these, 83 mutations were exon 19
deletions (42%), and 92 were L858R (47%). The study (5)
showed that patients with EGFR mutations survived longer
than those without mutations (p= 0.0046). There was no
difference in the overall survival between patients with an
exon 19 deletion and those with L858R (p= 0.41) (5).
In the Brazilian study conducted by Bacchi et al., the EGFR
mutation frequency was 30.4% (1). In that study, 169 of 207
patients (81%) had adenocarcinoma, and 38 of 207 (18.35%)
patients had a non-adenocarcinoma histology. Of the 207
patients, 120 (57.97%) were male. EGFR mutations were more
prevalent in the adenocarcinoma histological type and in non-
smokers than in non-adenocarcinoma histological types and
smokers, respectively. The Brazilian study did not show
differences between Asian and non-Asian patients regarding
the EGFR mutation frequencies. That study has a patient
selection bias. Despite the authors’ assertion that the study
sample represents all five Brazilian geographic regions, not all
of the NSCLC patients had the opportunity for EGFRmutation
assessment in their origin centers. The data were obtained from
the laboratory files, and this may be a source of bias. Among
the 63 patients with an EGFR mutation, 57 (90.04%) patients
presented with an adenocarcinoma histological type. In
previous studies, the rate of EGFR mutation in the adenocarci-
noma histological type was 49% (5). The gender distribution in
this study is another point of controversy. In the Brazilian
study, the proportion of male patients was 57.97% (120/207),
which was less than 75%, the previously published proportion
of male patients (2-4). Differences in histology and gender
distribution may lead to an unexpectedly higher frequency of
EGFR mutation in the Brazilian population (30.4%) than has
been reported in other publications (16.6–16.9%) (3,6) because
the adenocarcinoma histological type predominates in this
patient selection (1-3). As in any retrospective study, several
potential sources of bias cannot be ruled out, and the reader
should take this into consideration when reading the manu-
script. Despite these limitations, this study is important to
characterize the frequencies of EGFR mutations among
different populations and improve the systemic treatment
selection for patients with advanced NSCLC.
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